The FIREFISH study (BP39056) was a two-part, open-label trial evaluating the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of risdiplam in symptomatic infants with genetically confirmed Type 1 SMA and two copies of the SMN2 gene. This evidence concerns the gene SMN2 and spinal muscular atrophy, type 1.